Vanda Pharmaceuticals INC Form 4 insider transactions

Mihael Hristos Polymeropoulos, CEO of Vanda Pharmaceuticals, recently acquired 10,000 shares of company stock through open market purchases.

Joakim Wijkstrom, SVP and Chief Marketing Officer of Vanda Pharmaceuticals, disposed of shares to cover tax obligations related to vested RSUs.

Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals, reports disposition of shares to cover tax obligations related to RSU settlement.

Mihael Hristos Polymeropoulos, CEO of Vanda Pharmaceuticals, reports disposition of shares to cover tax obligations and acquisition of shares through open market purchases.

Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to RSU settlement.

Timothy Williams, SVP & General Counsel of Vanda Pharmaceuticals, reports the disposal of shares to cover tax obligations related to vested RSUs.

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, purchased 10,000 shares of common stock at $4.76 per share on February 28, 2025.

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, purchased 10,000 shares of common stock at $4.76 per share on February 27, 2025.

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, increased his holdings by purchasing 10,000 shares of VNDA common stock.

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, recently acquired 10,000 shares of common stock at an average price of $4.464 per share.

Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, recently purchased 2,000 shares of common stock at a price of $4.3894 per share.

Joakim Wijkstrom, SVP, Chief Marketing Officer of Vanda Pharmaceuticals, reports the acquisition of 125,000 shares of common stock through a restricted stock unit award.

Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals, acquired 450,000 shares of common stock through a restricted stock unit award.

Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, reports acquiring 125,000 shares of common stock via a restricted stock unit award.

Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals, acquired 125,000 shares of common stock through a restricted stock unit award.

Timothy Williams, SVP & General Counsel of Vanda Pharmaceuticals, reports acquiring 125,000 shares of common stock through a restricted stock unit award.

Stephen Ray Mitchell, a director at Vanda Pharmaceuticals, sold 5,000 shares of common stock at an average price of $5.1726 on November 14, 2024.

Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, reported the sale of 2,251 shares of common stock to cover tax obligations related to RSU settlement.

Director Phaedra Chrousos reports acquisition of stock options and restricted stock units in Vanda Pharmaceuticals.

Director Tage Honore reports acquisition of Vanda Pharmaceuticals stock and stock options, signaling potential confidence in the company's future.

Director Richard W. Dugan reports acquisition of Vanda Pharmaceuticals shares and stock options, signaling potential confidence in the company's future.

Director Stephen Ray Mitchell reports acquiring and disposing of Vanda Pharmaceuticals shares and stock options on May 17, 2024.

Director Anne Sempowski Ward reports acquiring shares through restricted stock units and stock options, while disposing of existing shares.

Timothy Williams, SVP & General Counsel of Vanda Pharmaceuticals, sold shares of common stock on March 4th and 5th, 2024, to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Joakim Wijkstrom, SVP, Chief Marketing Officer of Vanda Pharmaceuticals, reports selling shares of common stock to cover tax obligations related to vested RSUs.

Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, sold shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, sold shares of common stock on March 4th and 5th, 2024, to cover tax obligations related to the settlement of vested RSUs.

Gunther Birznieks, SVP of Business Development at Vanda Pharmaceuticals, sold shares of common stock on March 4th and 5th, 2024, to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).